Metastatic Breast Cancer Progression Post Antiestrogen Therapy — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for metastatic breast cancer progression post antiestrogen therapy. 3 active patents protecting 1 drugs from 1+ originators. First major cliff: 2034. Daily refresh.

1
Approved drugs
3
Active US patents
62/100
Avg vulnerability
—
Annual revenue covered

Originators in Metastatic Breast Cancer Progression Post Antiestrogen Therapy

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

AstraZeneca 3 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating metastatic breast cancer progression post antiestrogen therapy. Each bar = one year. Y-axis scaled to peak year (3 patents).

3
34

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Faslodex
fulvestrant
 AstraZeneca 3 62 — 2034-02-14

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9833459 Faslodex method of use 62 2034-02-14
10188663 Faslodex method of use 62 2034-02-14
9271990 Faslodex method of use 62 2034-05-17

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9271990 Faslodex method of use 62 2034-05-17
9833459 Faslodex method of use 62 2034-02-14
10188663 Faslodex method of use 62 2034-02-14

Related